ERVW-1 and amyotrophic lateral sclerosis: The HERV-K Env-su19–37 antibodies significantly correlated with clinical measures of disease severity, both in serum and cerebrospinal fluid, suggesting that increased circulating levels of the antibodies could serve as a possible early novel biomarker in patients with ALS (Arru et al., 2018).